142 related articles for article (PubMed ID: 17372138)
1. Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies.
Hoffmann LA; Krumbholz M; Faber H; Kuempfel T; Starck M; Pöllmann W; Meinl E; Hohlfeld R
Neurology; 2007 Mar; 68(12):958-9. PubMed ID: 17372138
[No Abstract] [Full Text] [Related]
2. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
[TBL] [Abstract][Full Text] [Related]
3. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
Hesse D; Sellebjerg F; Sorensen PS
Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.
Santos R; Weinstock-Guttman B; Tamaño-Blanco M; Badgett D; Zivadinov R; Justinger T; Munschauer F; Ramanathan M
J Neuroimmunol; 2006 Jul; 176(1-2):125-33. PubMed ID: 16698090
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for interferon response in MS: are we there yet?
Rudick RA; Ransohoff RM
Neurology; 2008 Mar; 70(13 Pt 2):1069-70. PubMed ID: 18362268
[No Abstract] [Full Text] [Related]
7. Antibodies against interferon-beta in multiple sclerosis.
Aarskog NK; Marøy T; Myhr KM; Vedeler CA
J Neuroimmunol; 2009 Jul; 212(1-2):148-50. PubMed ID: 19467718
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
[TBL] [Abstract][Full Text] [Related]
9. IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays.
Capra R; Sottini A; Cordioli C; Serana F; Chiarini M; Caimi L; Padovani A; Bergamaschi R; Imberti L
J Neuroimmunol; 2007 Sep; 189(1-2):102-10. PubMed ID: 17619058
[TBL] [Abstract][Full Text] [Related]
10. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
Millonig A; Rudzki D; Hölzl M; Ehling R; Gneiss C; Künz B; Berger T; Reindl M; Deisenhammer F
Mult Scler; 2009 Aug; 15(8):977-83. PubMed ID: 19465447
[TBL] [Abstract][Full Text] [Related]
11. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.
Pachner AR; Dail D; Pak E; Narayan K
J Neuroimmunol; 2005 Sep; 166(1-2):180-8. PubMed ID: 16005084
[TBL] [Abstract][Full Text] [Related]
12. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
Ravnborg M; Bendtzen K; Christensen O; Jensen PE; Hesse D; Tovey MG; Sørensen PS
Mult Scler; 2009 Mar; 15(3):323-8. PubMed ID: 19028832
[TBL] [Abstract][Full Text] [Related]
13. Increased CXCL8 (IL-8) expression in Multiple Sclerosis.
Lund BT; Ashikian N; Ta HQ; Chakryan Y; Manoukian K; Groshen S; Gilmore W; Cheema GS; Stohl W; Burnett ME; Ko D; Kachuck NJ; Weiner LP
J Neuroimmunol; 2004 Oct; 155(1-2):161-71. PubMed ID: 15342208
[TBL] [Abstract][Full Text] [Related]
14. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a.
Schwid SR; Decker MD; Lopez-Bresnahan M;
Neurology; 2005 Dec; 65(12):1964-6. PubMed ID: 16380621
[TBL] [Abstract][Full Text] [Related]
15. Interferon neutralizing antibodies in multiple sclerosis: a new perspective.
Phillips JT
Arch Neurol; 2010 Apr; 67(4):386-7. PubMed ID: 20385901
[No Abstract] [Full Text] [Related]
16. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?
Giovannoni G; Goodman A
Neurology; 2005 Jul; 65(1):6-8. PubMed ID: 16009876
[No Abstract] [Full Text] [Related]
17. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
Massart C; Gibassier J; Oger J; Le Page E; Edan G
Clin Chim Acta; 2007 Feb; 377(1-2):185-91. PubMed ID: 17123498
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a multiplex bead-based screening assay for detection of binding antibodies to interferon-beta.
Lapé Nixon M; Matud J; Yeh C; Prince HE
J Neuroimmunol; 2009 May; 210(1-2):104-7. PubMed ID: 19345423
[TBL] [Abstract][Full Text] [Related]
20. Evolution of interferon-beta binding antibodies in MS patients may predict development of neutralizing antibodies.
Mayr M; Berek K; Deisenhammer F
Eur J Neurol; 2003 Jul; 10(4):462-4. PubMed ID: 12823504
[No Abstract] [Full Text] [Related]
[Next] [New Search]
